Madam Speaker, as I said earlier, and I will say it again, part of our COVID pandemic response has been directly influenced and supported by the work of the microbiology lab, so it is quite important to talk about the significance of the pandemic during this debate.
I would also point out that there were no interruptions when hon. members of the Conservative Party spoke about Afghanistan, which was not directly related to this motion either. I would ask for the same consideration and opportunity to talk about the global pandemic. I will continue to wrap up my comments on the motion, but it is important groundwork in relation to the work of our scientists.
As we have stated before, we expect that COVID-19 vaccines will be available to every eligible Canadian who wants to be vaccinated by September. Let me assure everyone that the Government of Canada continues to hold regular discussions with provinces and territories, with a particular focus in the coming weeks on ensuring that capacity to administer vaccines is aligned with vaccine availability. This is just part of our commitment to provinces and territories that we stand together in the fight against COVID-19.
We are continuously working with our provincial and territorial partners to ensure they have the help they need to manage outbreaks and keep people safe, from purchasing vaccines and personal protective equipment to boosting rapid testing and contact tracing. Testing and contact tracing is an area in which the microbiology lab is very much involved.
In fact, $8 out of every $10 spent across our country to respond to the pandemic has come from the Government of Canada. Much of the support is being provided through the COVID-19 public health rapid surge capacity initiative. This initiative, in addition to the safe restart agreement, has provided the provinces and territories with more than $19 billion in federal investment. These investments support health care systems, capacity testing and contact tracing, and other social services for Canadians. This allows provinces and territories to respond more effectively to outbreaks and to mitigate transmission in hot zones where there is pressure on health care systems.
I will speak now about testing and screening, work in which the microbiology lab has been critical.
Testing and screening, along with public health measures and vaccination, are key to slowing the spread of COVID-19. As of May 18, nearly 27 million rapid tests have been shipped to provinces and territories. When combined with the federal allocation, more than 41 million rapid tests have been distributed across the country. Provinces and territories determine how to use the test based on the specific needs of their respective jurisdictions, informed by guidance from a variety of sources, including the federal government. The Government of Canada is encouraging jurisdictions to use rapid tests as part of their screening practices and as an additional layer of protection to help slow the spread of the virus.
The Government of Ontario recently launched a new online COVID-19 rapid testing program, the provincial antigen screening program, so essential businesses could access free rapid testing kits. This supports the province's rapid testing initiative for small and medium-sized enterprises through the Ontario Chamber of Commerce, a system and testing that has been directly influenced by the microbiology lab. The provincial antigen screening program provides free rapid antigen tests to screen for asymptomatic cases of COVID-19 in Ontario workplaces. Alberta will also offer free rapid antigen testing to businesses and not-for-profit organizations through chambers of commerce.
Rapid testing can help detect asymptomatic COVID-19 cases and help limit the spread by isolating these individuals early.
It is important for those administering rapid tests to be adequately trained. The Government of Canada has provided provinces and territories with guidance on the use of these tests through the federal testing and screening expert advisory panel; the industry advisory roundtable on COVID-19 testing, screening, tracing and data management; and the Public Health Agency of Canada's guidance on the use of antigen tests.
The Government of Canada will continue to work closely with provinces and territories to ensure they have the tools they need to respond to the pandemic, including procuring these point-of-care PCR tests and rapid tests. In addition to the public health measures already in place, this is another layer of protection to keep workers safe.
Our response to this pandemic continues to be driven by science. Our National Microbiology Laboratory in Winnipeg is known around the world for its scientific excellence. The work done at this world-class laboratory includes surveillance for infectious diseases, emergency outbreak preparedness and response, training, and research and development. It helps keep Canadians safe each and every day.
Canada is home to some of the most skilled and brightest researchers in the world, and they have been working hard to support domestic and international efforts to fight this virus. COVID-19 is a global pandemic, and it requires a global solution. The participation of researchers around the world to combat COVID-19 is truly a new model for global collaboration. We are proud of that as one of the global leaders in infectious disease research.
The National Microbiology Laboratory has been working tirelessly with Canadian and international partners on this front. Every day we are adding to our knowledge of COVID-19, keeping pace with the rapid growth of new scientific evidence as it emerges. In order to continue to slow and eventually stop the spread of infection, we need to continue to mobilize Canada's research and scientific communities to advance research and technology development.
That is why, in March 2020, the Government of Canada announced a $1 billion government-wide COVID-19 response fund, which includes $275 million to enhance our capacity to test antivirals, develop vaccines and support clinical trials. It is why what I was speaking about earlier in my speech is so critical to this.
Through the Canadian Institutes of Health Research rapid research response program, the Government of Canada has invested a total of $54.2 million to support 99 research teams from across Canada. These teams are focusing on developing and implementing measures to rapidly detect, manage and reduce transmission of COVID-19. This includes vaccine research and the development of strategies to combat stigma, misinformation and fear.
Canada's public health advice will continue to be based on trusted, expert science provided by our National Microbiology Laboratory scientists and our international partners.
Let me also answer some questions regarding former employees of the National Microbiology Laboratory. The two scientists in question are no longer employed by the Public Health Agency of Canada. We cannot disclose additional information for privacy and confidentiality reasons. However, I can say that the National Microbiology Laboratory will continue to play a critical role in protecting the health and safety of Canadians.
We are committed to supporting open, collaborative research while also protecting our research, our national security and our economic interests. Outside interference poses real threats to Canadian research security. This is a threat we have always taken seriously. In 2020, public safety officials met with more than 34 universities to help ensure the safety and security of their research, and CSIS has engaged more than 225 different organizations, including universities, to ensure they are aware of foreign threats.
In March, the Minister of Innovation, Science and Industry requested the development of specific guidelines that incorporate national security into the evaluation of any research partnerships. As we move forward in our fight against COVID-19, we continue to ensure that we welcome the international scientific community. At the same time, we will work with our security agencies to help keep Canadians safe.
To date, more than 22 million doses of COVID-19 vaccines have been administered in Canada. Relatively few cases of the virus have been reported among people who have received at least one dose of COVID-19 vaccine, and fewer still among those who have received two doses. We must remember that vaccines take time to work, including up to 14 days after the first dose, to provide good protection, and up to seven days after the second dose to provide strong protection.
Based on data provided by nine provinces and territories up to May 25, people with infections occurring 14 days or more after their first dose accounted for 0.15% of people who had received at least one dose of the COVID-19 vaccine. Compared with unvaccinated cases in these jurisdictions, these individuals were more likely to report no symptoms and less likely to experience severe illness requiring hospitalization. This aligns well with vaccine effectiveness studies showing strong protection against severe illness.
The good news is that nationally, we expect the third wave to continue to decline as long as we maintain current measures and do not increase in-person contact rates around the community. The downward trends show that measures put in place across the country are working to suppress the third wave as vaccination continues. Things have taken a great turn for the better, but we always need to stay the course.